Search Results 8171-8180 of 42588 for oral

1. Tradipitant After GLP-1R Agonist In Healthy, Overweight, Or Class I Or II Obese Volunteers - Mayo Clinic

   Previous experience with an oral or injectable GLP-1 agonist;; Use of the following within 2 weeks of screening: an other GLP-1 agonist, an NK-1 antagonist ...

2. Voriconazole (intravenous route) - Side effects & uses - Mayo Clinic

   Your doctor will give you or your child a few doses of this medicine until your condition improves, and then switch you to an oral medicine that works the same ...

3. Head and Neck Cancer Center - Doctors - Mayo Clinic

   outh care, Dental surgery, Oral appliance therapy, Cancer, Oral and throat cancer, Mouth cancer, Head and neck cancer, Facial deformity, Jaw tumors and ...

4. Study of INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma - Mayo Clinic

   eceived therapeutic oral or IV antibiotics within 2 weeks prior to Day 0;; History or current evidence of any condition, therapy or laboratory abnormality ...

5. An Extension Study Monitoring the Safety of Patients with Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 - Mayo Clinic

   ... oral contraceptive pill or transdermal patch, spermicide and barrier [condoms], intrauterine device, implants for contraception, injections for ...

6. A Study To Evaluate The Safety And Tolerability Of TreT In Subjects With PAH Currently Using Tyvaso - Mayo Clinic

   Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable), intrauterine ...

7. A Study of the Effectiveness and Safety of CTL019 in Adult Patients with Diffuse Large B-Cell Lymphoma - Mayo Clinic

   Patients on oral anticoagulation therapy; Prior treatment with any adoptive T cell therapy; Patients with active neurological auto immune or inflammatory ...

8. A Study Using the New TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients with Metastatic, Persistent, Recurrent, or Progressive Solid Tumors - Mayo Clinic

   Treatment with oral or parenteral corticosteroids dosed greater than 40 mg hydrocortisone daily or its equivalent (e.g., prednisone 10 mg, prednisolone 8 mg ...

9. High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma - Mayo Clinic

   Endocrine therapy: No concurrent systemic corticosteroids including oral steroids (i.e., prednisone, dexamethasone), topical steroid creams or ointments, or any ...

10. Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors - Mayo Clinic

    Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any ...